Medical coding and SAE reconciliation are sometimes treated as technical data management activities. In reality, they have a direct impact on safety review, clinical interpretation, statistical analysis, regulatory reporting, and inspection readiness.When coding is inconsistent or reconciliation is delayed, the effects can appear throughout the study lifecycle. Safety signals may be harder to interpret. Medical review may be less efficient. Analysis outputs may require additional explanation. Database lock may be delayed. Inspection questions may become more difficult to answer.

For sponsors, medical coding and SAE reconciliation should not be viewed as end-stage cleanup tasks. They should be planned, controlled, reviewed, and documented as part of the broader clinical data management strategy.

What is medical coding in clinical trials?

Medical coding is the process of mapping verbatim clinical terms collected during a study to standardized medical dictionaries. This allows data to be reviewed, analyzed, summarized, and reported consistently.

Common examples include:

• Adverse events coded using MedDRA
• Medical history coded using MedDRA
• Concomitant medications coded using WHODrug
• Procedures or other clinical terms coded using appropriate controlled terminology, depending on study needs

Coding transforms site-entered or investigator-reported terms into standardized terms that can be grouped, analyzed, and interpreted. This is critical for safety review and for consistent reporting across sites, countries, studies, and programs.

Why medical coding matters beyond the coding task?

Medical coding is often operationally simple to describe, but complex to execute well.

A coded term is not just a label. It affects how events are grouped, how tables are produced, how safety data are interpreted, and how study outputs are reviewed. Inconsistent coding can lead to fragmented safety information, misleading summaries, or unnecessary review cycles.

For example, similar verbatim adverse event terms may be coded differently if coding rules are unclear or if review is inconsistent. Medication names may be incomplete, misspelled, or entered using local brand names. Medical history terms may lack sufficient detail. Ambiguous verbatims may require queries or medical input.

The goal is not only to assign dictionary terms. The goal is to support consistent, defensible, and clinically meaningful interpretation of the data.

What Sponsors Need to Know About MedDRA and WHODrug?

Sponsors do not need to manage every operational detail of dictionary coding, but they should understand the implications of coding strategy and quality control.

MedDRA is commonly used for adverse events, medical history, and other medical concepts. It provides a hierarchical structure that allows terms to be grouped at different levels for review and reporting.

WHODrug is commonly used for concomitant medications and other drug-related data. It supports standardized identification and classification of medications across countries, brands, substances, and formulations.

The key sponsor considerations include:

• Which dictionary versions will be used?
• How will dictionary version updates be managed?
• What is the coding frequency?
• What quality control process will be applied?
• How will ambiguous or incomplete verbatim terms be handled?
• When is medical input required?
• How will coding decisions be documented?
• How will coding status be tracked before interim analysis or database lock?

These decisions should be documented in the data management plan or coding plan, not handled informally during study execution.

Common medical coding challenges

Medical coding issues often arise because clinical trial data are entered by different sites, in different countries, and under real operational constraints. Common challenges include:

• Ambiguous verbatim terms
• Incomplete adverse event descriptions
• Medication names entered as local brands
• Misspellings or abbreviations
• Combination medications
• Inconsistent use of severity or diagnosis terms
• Multiple similar entries for the same concept
• Changes in dictionary versions
• Terms requiring medical review
• Late coding review close to database lock

These issues are not unusual. What matters is whether the study has a clear process for identifying, resolving, documenting, and quality controlling them.

Why Coding Review Should Start Early?

Coding review should not wait until the end of the study. Late coding review can create pressure on data management, clinical, safety, and medical teams, especially if coding decisions require clarification from sites or medical review.

Routine coding review supports:

• Earlier identification of ambiguous verbatims
• Timely queries where clarification is needed
• Consistent coding decisions across similar terms
• Better medical and safety review
• More predictable database lock preparation
• Reduced late-stage rework

For studies with interim analysis, safety monitoring, or fast-moving enrollment, coding cadence becomes even more important.

What is SAE reconciliation?

SAE reconciliation is the process of comparing serious adverse event data in the clinical database with corresponding data in the safety database. The purpose is to identify and resolve inconsistencies between systems.

In many studies, SAE data are captured or managed in more than one place. Clinical data may be entered in the EDC, while safety data may be captured in a pharmacovigilance or safety database. Because these systems serve different operational purposes, discrepancies can occur.

SAE reconciliation helps ensure that serious adverse event information is consistent, complete, and traceable across systems.

Common SAE reconciliation fields

The exact scope of SAE reconciliation depends on the study and sponsor requirements, but common fields may include:

• Subject identifier
• Site number
• Event term
• Seriousness criteria
• Onset date
• End date or resolution date
• Outcome
• Severity
• Relationship or causality
• Action taken
• Treatment or intervention information
• Death-related information, if applicable
• Follow-up status

The reconciliation plan should define which fields are included, how discrepancies are categorized, and how resolution is documented.

Common SAE reconciliation issues

SAE reconciliation can reveal a range of discrepancies, including:

• SAE present in one system but missing in the other
• Event term mismatch
• Onset date mismatch
• Outcome mismatch
• Seriousness criteria mismatch
• Causality mismatch
• Severity mismatch
• Follow-up information not updated consistently
• Duplicate or merged events
• Differences in event splitting or grouping
• Resolution date discrepancies

Some discrepancies are administrative. Others may affect safety interpretation or regulatory reporting. A mature process distinguishes between discrepancy types and prioritizes resolution based on risk and impact.

Why SAE reconciliation should not be left to the end?

Late SAE reconciliation is risky because discrepancy resolution often requires input from several teams, including data management, safety, clinical operations, medical monitoring, and sometimes sites or investigators.

If reconciliation is performed only near database lock, teams may face unresolved safety discrepancies at the same time they are trying to complete final data cleaning, coding, external data reconciliation, listing review, and statistical programming handoff.

Routine SAE reconciliation helps identify issues earlier and allows teams to resolve them while study context is still fresh.

It also supports stronger oversight. A recurring discrepancy pattern may indicate a process issue, system mismatch, site training gap, or communication problem between clinical and safety teams.

The relationship between coding, SAE reconciliation, and analysis readiness

Coding and SAE reconciliation are closely connected to analysis readiness.

If adverse events are not coded consistently, safety tables may not reflect the data clearly. If concomitant medications are incomplete or inconsistently coded, review may be more difficult. If SAE data are not reconciled, discrepancies may create uncertainty in final outputs.

Statistical programming teams rely on structured, consistent, and finalized data. Medical writers rely on data outputs that can be interpreted and described with confidence. Sponsors rely on outputs that can withstand internal review, regulatory questions, and inspection scrutiny.

This is why coding and reconciliation should be connected to the broader biometrics workflow rather than managed as isolated tasks.

The Importance of Quality Control and Documentation

Strong coding and SAE reconciliation processes require more than task completion. They require quality control and documentation.

Key elements include:

• Defined coding conventions
• Dictionary version control
• Coding review frequency
• QC sampling or full QC approach, depending on study requirements
• Medical review escalation process
• Reconciliation specification
• Discrepancy categories
• Resolution workflow
• Audit trail and documentation of changes
• Status tracking for interim analysis and database lock

Documentation is especially important for inspection readiness. Sponsors should be able to show not only that coding and reconciliation were performed, but how decisions were made and how issues were resolved.

How Bioforum Drives Confidence in Coding and SAE Reconciliation?

Bioforum’s clinical data management teams support medical coding, coding quality control, SAE reconciliation, and data review workflows that are designed for consistency, traceability, and regulatory confidence.

Our teams work across data management, clinical review, safety-related workflows, biostatistics, statistical programming, and medical writing to help ensure that study data are not only cleaned, but also structured and reviewed in a way that supports analysis and reporting.

For sponsors, this cross-functional perspective is valuable because coding and reconciliation issues rarely remain within one function. They affect safety review, database lock, analysis outputs, and the quality of study reporting.

Why Coding and Reconciliation Deserve a Seat at the Strategy Table?

Medical coding and SAE reconciliation are essential components of clinical data quality.

When they are planned early, reviewed routinely, quality controlled, and documented clearly, they support safety interpretation, analysis readiness, regulatory confidence, and smoother database lock preparation.

When they are left until late in the study, they can create avoidable risk and operational pressure.

For sponsors, the question is not only whether coding and reconciliation are being performed. The stronger question is whether they are being managed as part of a controlled, cross-functional clinical data strategy.

Trusted Expertise for Complex Clinical Data

Need support with medical coding, SAE reconciliation, or clinical data review? Bioforum’s data management experts can help maintain consistency, traceability, and inspection readiness across your study data.